NEW YORK (360Dx) – Saladax Biomedical today said that it has received CE marking for its first two products in the new MyCare Psychiatry line of rapid tests for antipsychotics.
The tests, MyCare Total Risperidone Assay Kit and MyCare Paliperidone Assay Kit, measure total risperidone or paliperidone in patients' blood. They are for use in clinical chemistry laboratories on high-throughput instruments and can help guide physicians in their decision-making process by providing objective evidence of medication levels within a clinically relevant time, Saladax said.
DeWayne Davenport vice president of strategic initiatives at the company, noted that in certain settings, results from Saladax's tests can be achieved in one hour from a blood draw, and within 48 hours in many other settings. Other methods can take a week or longer.
"Doctors now have a new tool to provide greater clarity on the cause of treatment failure that may help distinguish medication nonresponse from lack of adherence," he said.
Saladax said that the MyCare Psychiatry line will include tests for total risperidone, paliperidone, clozapine, olanzapine, quetiapine, and total aripiprazole. CE marking is expected for all six tests by the end of the year, the firm added.